Orbimed Advisors LLC Corvus Pharmaceuticals, Inc. Put Options Transaction History
Orbimed Advisors LLC
- $2.8 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CRVS
# of Institutions
101Shares Held
38.9MCall Options Held
98.5KPut Options Held
226K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.04MShares$51.6 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$24 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$24 Million9.69% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$19.6 Million0.16% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.23MShares$16.4 Million1.89% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $341M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...